Catalyst

Slingshot members are tracking this event:

Impax Receives Tentative FDA Approval for Generic Version of Vytorin (ezetimibe and simvastatin) Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
IPXL

100%

Additional Information

Additional Relevant Details Impax has received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for the generic version of the ezetimibe and simvastatin containing tablets, in 10 mg / 10 mg, 10 mg / 20 mg, 10 mg / 40 mg and 10 mg / 80 mg strengths.
http://investors.imp...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 02, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Vytorin, Generic, Anda, Tentative Approval